Claims for Patent: 10,195,183

Summary for Patent: 10,195,183

Title:	Compositions and methods for treating chronic urticaria
Abstract:	Disclosed herein are methods of treating conditions, which may be associated with elevated levels of mast cells, basophils, eosinophils, or a combination thereof, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
Inventor(s):	Bozik; Michael E (Pittsburgh, PA), Dworetzky; Steven (Pittsburgh, PA)
Assignee:	Knopp Biosciences LLC (Pittsburgh, PA)
Application Number:	15/675,912
Patent Claims:	1. A method of treating chronic idiopathic urticaria comprising administering to a subject in need thereof a therapeutically effective amount of dexpramipexole. 2. The method of claim 1, wherein the therapeutically effective dose is selected from the group consisting of about 1 mg to about 1,000 mg per day, about 50 mg to about 600 mg per day, and about 150 mg to about 300 mg per day. 3. The method of claim 1, wherein the therapeutically effective amount is selected from the group consisting of at least about 150 mg, at least about 300 mg, and at least about 600 mg. 4. The method of claim 1, wherein administering is selected from the group consisting of administering a fraction of the therapeutically effective amount two or more times per day, administering an amount equal to about half of the therapeutically effective amount twice per day, and administering the therapeutically effective amount every 12 hours. 5. The method of claim 1, wherein administering comprises administering about 150 mg two times per day. 6. The method of claim 1, further comprising an induction step, wherein said induction step is selected from the group consisting of administering a therapeutic agent that is capable of decreasing mast cell levels, decreasing basophil levels, decreasing eosinophil levels, decreasing the activation level of mast cells, decreasing the activation level of basophils, decreasing the activation level of eosinophils, and a combination thereof. 7. The method of claim 6, wherein the therapeutic agent is selected from the group consisting of a glucocorticoid, a corticosteroid, a non-steroidal anti-inflammatory drug (NSAID), a tyrosine kinase inhibitor, a fusion protein, a monoclonal antibody directed against one or more pro-inflammatory cytokines, a chemotherapeutic agent, a phenolic antioxidant, an anti-proliferative drug, an anti IL-5 monoclonal antibody, an IL-5 receptor monoclonal antibody, an anti IL-13 monoclonal antibody, an anti IL-13 receptor monoclonal antibody, an anti IL-4 monoclonal antibody, an anti IL-4 receptor monoclonal antibody, an anti IgE monoclonal antibody, a TNF-.alpha. inhibitor, a fusion protein, an anti-inflammatory drug, and a combination thereof. 8. The method of claim 7, wherein the tyrosine kinase inhibitor is imatinib. 9. The method of claim 7, wherein the anti IL-5 monoclonal antibody is selected from the group consisting of mepolizumab and reslizumab. 10. The method of claim 7, wherein the IL-5 receptor monoclonal antibody is benralizumab. 11. The method of claim 7, wherein the anti IL-13 monoclonal antibody is lebrikizumab. 12. The method of claim 7, wherein the anti IL-4 receptor monoclonal antibody is dupilumab. 13. The method of claim 7, wherein the anti IgE monoclonal antibody is omalizumab. 14. The method of claim 7, wherein the TNF-.alpha. inhibitor is selected from the group consisting of infliximab, adalimumab, certolizumab pegol, and golimumab. 15. The method of claim 7, wherein the fusion protein is etanercept. 16. The method of claim 1, wherein administering comprises administering about 75 mg two times per day. 17. The method of claim 1, wherein administering comprises administering about 300 mg two times per day. 18. The method of claim 1, wherein the therapeutically effective amount of dexpramipexole is administered as an initial dosing regimen and then as a maintenance dosing regimen. 19. The method of claim 18, wherein the therapeutically effective amount of the initial dosing regimen is selected from the group consisting of about 50 mg to about 1500 mg per day, about 150 mg to about 300 mg per day, about 300 mg to about 500 mg per day, and about 300 mg to about 600 mg per day. 20. The method of claim 18, wherein the therapeutically effective amount of the maintenance dosing regimen is selected from the group consisting of about 50 mg to about 1500 mg per day, about 150 mg to about 300 mg per day, about 300 mg to about 500 mg per day, and about 300 mg to about 600 mg per day. 21. The method of claim 1, wherein the therapeutically effective amount is administered orally. 22. The method of claim 1, wherein the therapeutically effective amount is administered topically.

Details for Patent 10,195,183

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	August 24, 1998	10,195,183	2033-08-13
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	10,195,183	2033-08-13
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	10,195,183	2033-08-13
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	10,195,183	2033-08-13
Immunex Corporation	ENBREL	etanercept	Injection	103795	February 01, 2007	10,195,183	2033-08-13
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	September 14, 2017	10,195,183	2033-08-13
Immunex Corporation	ENBREL	etanercept	Injection	103795		10,195,183	2033-08-13